SRR2780299
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.300
- MYC_TARGETS_V2+0.300
- PROTEIN_SECRETION+0.300
- DNA_REPAIR+0.200
- E2F_TARGETS+0.200
- FATTY_ACID_METABOLISM+0.200
- MYC_TARGETS_V1+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- BILE_ACID_METABOLISM+0.100
- INTERFERON_GAMMA_RESPONSE+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- APICAL_JUNCTION-0.400
- ESTROGEN_RESPONSE_EARLY-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COAGULATION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- HEDGEHOG_SIGNALING-0.300
- HYPOXIA-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9R4-01A-11R-A38B-07 | — | — | 0.868 |
| 2 | fe4a0710-a6db-4735-9d1a-113df310def6 | — | — | 0.859 |
| 3 | TCGA-A8-A06T-01A-11R-A00Z-07 | — | B | 0.856 |
| 4 | MNG373 | — | — | 0.855 |
| 5 | ERR2208947 | — | — | 0.843 |
| 6 | TCGA-A2-A0ET-01A-31R-A034-07 | — | B | 0.840 |
| 7 | SAMN03290898 | — | — | 0.835 |
| 8 | BS_2A5R9MEJ | high-grade glioma | — | 0.833 |
| 9 | 88328 | EPN | Supratentorial EPN | 0.825 |
| 10 | BS_QB7YGKN1 | Glial-neuronal tumor NOS | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |